STOCK TITAN

Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions. On July 1, 2026 he received an option to buy 39,823 shares of common stock at $77.01 per share and a grant of 16,232 restricted stock units.

On June 30, 2026 10,000 restricted stock units vested and were settled in common shares, with 5,408 shares withheld by the company to cover tax obligations and 4,592 shares remaining directly owned. The filing shows routine grants, vesting, and tax withholding rather than open-market trading.

Positive

  • None.

Negative

  • None.
Insider RAMSAY DAVID A
Role EVP, PRESIDENT, DRUG DELIVERY
Type Security Shares Price Value
Grant/Award Restricted Stock Units 16,232 $0.00 --
Grant/Award Option to Purchase Common Stock 39,823 $0.00 --
Exercise Restricted Stock Units 10,000 $0.00 --
Exercise Common Stock 10,000 $0.00 --
Tax Withholding Common Stock 5,408 $78.27 $423K
Holdings After Transaction: Restricted Stock Units — 16,232 shares (Direct, null); Option to Purchase Common Stock — 39,823 shares (Direct, null); Common Stock — 10,000 shares (Direct, null)
Footnotes (1)
  1. The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. This option vests one-fourth on such date and then 1/48th monthly thereafter.
Stock option grant 39,823 shares at $77.01 Option to purchase common stock granted July 1, 2026
RSU grant 16,232 units Restricted stock units granted July 1, 2026
RSU vesting 10,000 units Restricted stock units vested June 30, 2026
Tax withholding shares 5,408 shares at $78.27 Shares withheld to satisfy tax obligations June 30, 2026
Shares held after withholding 4,592 shares Common stock directly owned after June 30, 2026 tax withholding
Option expiration July 1, 2036 Expiration date of 39,823-share stock option
Restricted Stock Units financial
"This transaction represents the vesting and settlement of restricted stock units in shares of common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"represents the shares that were withheld by the issuer as payment for tax withholding obligations"
vests one-fourth on the first anniversary financial
"This award vests one-fourth on the first anniversary of the grant date"
Exercise or conversion of derivative security financial
"transaction code description: Exercise or conversion of derivative security"
one-year holding period financial
"The shares received upon vesting remain subject to a one-year holding period from the vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RAMSAY DAVID A

(Last)(First)(Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, PRESIDENT, DRUG DELIVERY
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/30/2026M10,000A$010,000D
Common Stock06/30/2026F5,408(1)D$78.274,592D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$006/30/2026M10,000 (2) (2)Common Stock10,000$00D
Restricted Stock Units$007/01/2026A16,23207/01/2027(3) (3)Common Stock16,232$016,232D
Option to Purchase Common Stock$77.0107/01/2026A39,82307/01/2027(4)07/01/2036Common Stock39,823$039,823D
Explanation of Responses:
1. The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
2. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
3. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
4. This option vests one-fourth on such date and then 1/48th monthly thereafter.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did HALO EVP David A. Ramsay receive in this Form 4?

David A. Ramsay received an option for 39,823 shares at $77.01 per share and a grant of 16,232 restricted stock units. These are compensation-related awards, not open-market stock purchases, and provide potential future ownership in Halozyme common stock.

How many Halozyme shares were involved in the June 30, 2026 RSU vesting for HALO EVP?

On June 30, 2026, 10,000 restricted stock units vested and settled into common shares. Of these, 5,408 shares were withheld to cover tax obligations, and 4,592 shares remained directly owned by David A. Ramsay after the tax withholding transaction.

Was there an open-market stock sale or purchase by HALO EVP David Ramsay?

The Form 4 shows no open-market buys or sells. Reported transactions are equity awards, option exercises, RSU vesting, and 5,408 shares withheld by Halozyme to pay tax obligations, which is not a discretionary market sale by the executive.

What are the vesting terms of the new Halozyme stock option granted to the EVP?

The new option for 39,823 shares at $77.01 vests one-fourth on the first anniversary of the grant date, then 1/48th monthly thereafter. This schedule gradually delivers exercisable options over several years, aligning part of compensation with longer-term company performance.

What are the vesting terms of the new restricted stock units granted to the HALO EVP?

The award of 16,232 restricted stock units vests one-fourth on the first anniversary of the grant date and one-fourth on each anniversary thereafter. This four-year vesting structure is designed to retain the executive and tie compensation to sustained service and company results.

How many Halozyme shares does the EVP hold directly after the tax withholding event?

Following the June 30, 2026 tax withholding event, David A. Ramsay directly held 4,592 shares of common stock from that specific RSU vesting. This figure reflects the shares remaining after 5,408 shares were withheld by Halozyme to satisfy tax obligations.